Industry News

Celularity and Verséa Ophthalmics team up to bring innovative ocular treatments to patients

Celularity Inc and Verséa Ophthalmics, LLC have entered an exclusive U.S. commercialization agreement to distribute Celularity's Biovance and Biovance 3L Ocular products. These placental-derived allografts provide a biological membrane covering for treating ocular surface disease and ocular surgical applications. Biovance 3L Ocular, an acellular 3-layer amniotic membrane, supports the treatment...